Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer

doi:10.12998/wjcc.v11.i36.8447

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 36

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1704)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

861

Figures (1-5)

221

Tables (1-4)

202

Sum=1335

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

239

Sum=308

Dec 26, 2023 (publication date) through Nov 30, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Dec 26, 2023; 11(36): 8447-8457
Published online Dec 26, 2023. doi: 10.12998/wjcc.v11.i36.8447

Table 4 Diagnostic performance of ¹⁸Fluorodeoxyglucose positron emission tomography computed tomography studies in the literature

Ref.	Modality	n	Status of the BCa	Sensitivity, %	Specifity, %
Drieskens et al[14]	FDG-PET/CT	55	Metastatic BCa	60	88
Apolo et al[16]	FDG-PET/CT	47	Metastatic BCa	88	87
Liu et al[33]	FDG-PET/CT	55	Metastatic BCa	77	97
Lu et al[15]	FDG-PET/CT	-	Metastatic BCa	89	82

Average values from meta-analysis of 4 individual positron emission tomography/computed tomography studies. BCa: Bladder cancer; FDG-PET/CT: Fluorodeoxyglucose positron emission tomography computed tomography.

Citation: Öztürk H, Karapolat İ. Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer. World J Clin Cases 2023; 11(36): 8447-8457
URL: https://www.wjgnet.com/2307-8960/full/v11/i36/8447.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i36.8447